Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv3
  2. Site details revised at 1 of 2 sitesv2
  3. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Rigel Pharmaceuticals
5 trials monitored
See all monitored trials
Leukemia
2,976 trials monitored
See 183 trials at risk
Acute Myeloid Leukemia (AML)
1,278 trials monitored
See 77 trials at risk
Glioma
1,260 trials monitored
See 93 trials at risk
and 1 more disease
A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.
Trial Details
NCT Number NCT07486713
Lead Sponsor Rigel Pharmaceuticals
Conditions
(from sponsor)		 AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma, Solid Tumor Malignancies
Related terms Cholangiocarcinoma, Glioma, Leukemia, Myeloid, Acute, Neoplasms
Enrollment 16 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov